Intelligent Bio Solutions Inc. (INBS) - Total Liabilities
Based on the latest financial reports, Intelligent Bio Solutions Inc. (INBS) has total liabilities worth $6.61 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Intelligent Bio Solutions Inc. - Total Liabilities Trend (2017–2025)
This chart illustrates how Intelligent Bio Solutions Inc.'s total liabilities have evolved over time, based on quarterly financial data. See INBS net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Intelligent Bio Solutions Inc. Competitors by Total Liabilities
The table below lists competitors of Intelligent Bio Solutions Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ChargePanel AB
ST:CHARGE
|
Sweden | Skr8.62 Million |
|
Bullfrog AI Holdings, Inc. Common Stock
NASDAQ:BFRG
|
USA | $758.70K |
|
Iqstel Inc
NASDAQ:IQST
|
USA | $30.23 Million |
|
Charan Insurance Public Company Limited
BK:CHARAN
|
Thailand | ฿321.06 Million |
|
BIRKS GROUP INC. A
F:2BG
|
Germany | €233.73 Million |
|
Xylo Technologies Ltd.
NASDAQ:XYLO
|
USA | $19.96 Million |
|
The Calmer Co International Ltd
AU:CCO
|
Australia | AU$5.31 Million |
|
Professional Diversity Network Inc
NASDAQ:IPDN
|
USA | $6.69 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Intelligent Bio Solutions Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see INBS stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.83 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.66 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Intelligent Bio Solutions Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Intelligent Bio Solutions Inc. (2017–2025)
The table below shows the annual total liabilities of Intelligent Bio Solutions Inc. from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $5.44 Million | -2.85% |
| 2024-06-30 | $5.60 Million | -16.08% |
| 2023-06-30 | $6.67 Million | +14.83% |
| 2022-06-30 | $5.81 Million | -15.27% |
| 2021-06-30 | $6.85 Million | -10.89% |
| 2020-06-30 | $7.69 Million | +21.97% |
| 2019-06-30 | $6.31 Million | +13.41% |
| 2018-06-30 | $5.56 Million | -15.50% |
| 2017-06-30 | $6.58 Million | -- |
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform. The compan… Read more